New drugs targeting norepinephrine transporter to treat hard-to-treat neuroblastoma in children
Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastoma
This study is testing new types of medicines that aim to better target and treat neuroblastoma, a tough childhood cancer, by delivering the drugs right to the tumor while protecting healthy cells, and it may involve patients in trials to see how safe and effective these treatments are.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10874468 on NIH RePORTER |
What this research studies
This research investigates innovative prodrugs designed to specifically target the norepinephrine transporter (NET) in neuroblastoma, a severe type of cancer affecting children. By enhancing drug delivery directly to the tumor cells while minimizing damage to healthy tissues, the study aims to improve treatment outcomes for patients with refractory neuroblastoma. The approach combines targeted drug action with a unique uptake mechanism to ensure that the therapeutic effects are concentrated in the tumor environment. Patients may be involved in trials assessing the safety and effectiveness of these new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with high-risk neuroblastoma that has not responded to standard treatments.
Not a fit: Patients with neuroblastoma that is not classified as refractory or those outside the age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for children suffering from refractory neuroblastoma.
How similar studies have performed: Previous research has shown promise in targeting the norepinephrine transporter in cancer therapies, indicating potential for success with this novel approach.
Where this research is happening
Philadelphia, United States
- Children's Hosp of Philadelphia — Philadelphia, United States (Active)
Researchers
- Principal investigator: Chorny, Michael — Children's Hosp of Philadelphia
- Study coordinator: Chorny, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.